# OnCo record kelonia-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/kelonia-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "kelonia-therapeutics" ;
  schema:name "Kelonia Therapeutics"@en ;
  schema:description "Kelonia developed a way to create CAR T cells directly inside the body using a targeted gene delivery particle, so patients do not need their cells removed and manufactured. Its lead programme is for multiple myeloma and Eli Lilly agreed to buy the company in 2026 for up to $7 billion."@en ;
  schema:url <https://onco.cc/companies/kelonia-therapeutics/>, <https://keloniatx.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://keloniatx.com/>, <https://keloniatx.com/pipeline/>, <https://www.prnewswire.com/news-releases/lilly-to-acquire-kelonia-therapeutics-to-advance-in-vivo-car-t-cell-therapies-302747122.html>, <https://www.sec.gov/Archives/edgar/data/1925270/000192527022000002/primary_doc.xml> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/> ;
  onco:technologies <https://onco.cc/technologies/in-vivo-car-t/> ;
  onco:targets <https://onco.cc/targets/bcma/>, <https://onco.cc/targets/cd19/> .